XL-784 - 10mM in DMSO , CAS No.1224964-36-6

CAS: 1224964-36-6 Cat. No.: X655280 分子式: C₂₁H₂₁ClF₂N₃O₈S^- 分子量: 548.92 PubChem CID: 74439626

グレード＆純度 10mM in DMSO

Storage

Desiccated,Store at -80°C

Shipped In

Dry ice packs + Cold packs

概要

XL-784 is a selective matrix metalloproteinases (MMP) inhibitor, with IC 50 s of ~1900, 0.81, 120, 10.8, 18, 0.56 nM for MMP-1 ，MMP-2， MMP-3 ，MMP-8，MMP-9， MMP-13 ，respectively.

In Vitro

XL-784 is a highly potent, low-molecular-weight (1,122 g/mol) inhibitor of MMPs that has very limited aqueous solubility (20 μg/mL). XL-784 potently inhibits MMP-2, MMP-13, and\nADAM10 [TNF-α-converting enzyme (TACE)] activity in vitro, with IC 50 values in the range of 1-2 nM. XL-784 also inhibits MMP-9 (IC 50 ~20 nM) activity and ADAM17 (IC 50 ~70 nM) also known as TACE. However, it exhibits low potency for inhibition of MMP-1 (IC 50 ~2,000 nM). MCE has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

All mice tolerate the treatments similarly. Control mice all developed aneurysms with a mean %△AD of 158.5%±4.3%. Treatment with all doses of XL-784 and doxycycline are effective in inhibiting aortic dilatation. There is a clear dose-response relationship between XL-784 and reductions in aortic dilatation at harvest (50 mg/kg 140.4% ±3.2%; 125 mg/kg 129.3% ±5.1%; 250 mg/kg 119.2%±3.5%; all Ps <0.01 compared to control). This continues with the higher doses (375 mg/kg 88.6%±4.4%; 500 mg/kg 76.0%±3.5%). The highest 2 doses of XL-784 tested are more effective than doxycycline (112.2%±2.0%, P<0.05) in inhibiting maximal dilatation of the aorta after elastase perfusion. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal administration

Mice A total of 89 mice undergo aortic perfusion. Beginning the day of perfusion, animals are treated with the study drug (e.g., XL-784), a negative control, or doxycycline. 76 animals survive to sacrifice and are included in the analysis. Animals treated with the experimental agent, XL-784 , receive gavage daily with the agent diluted in 0.1 mL of Cremophor, a nonionic castor oil-based solubilizer and emulsifying agent. Three doses of the drug are used, 50 (n=17), 125 (n=17), and 250 mg/kg per d (n=18) administered as a single daily dose. The fifth group of mice do not receive a gavage treatment but are treated with doxycycline (n=19) in their drinking water at a concentration 100 mg/kg per d of the animals. In the second treatment protocol, a total of 50 animals underwent aortic perfusion and 47 animals survive for analysis at 14 days. The 5 treatment groups are XL-784 at 250, 375, or 500 mg/kg , Cremaphor diluent alone, or doxycycline 100 mg/kg. Animals are assigned in groups of 3 to a treatment group rotating randomly through each treatment group until there are 9 animals in each group except for the 500 mg/kg per d group which totaled to 14 animals . aladdin has not independently confirmed the accuracy of these methods. They are for reference only.

IC50& Target:MMP-2 0.81 nM (IC 50 ) MMP13 0.56 nM (IC 50 ) MMP-8 10.8 nM (IC 50 ) MMP-9 18 nM (IC 50 ) MMP-3 120 nM (IC 50 ) MMP-1 1900 nM (IC 50 )

仕様

仕様と純度

10mM in DMSO

生化学的・生理学的メカニズム

XL-784 is a selective matrix metalloproteinases (MMP) inhibitor, with IC 50 s of ~1900, 0.81, 120, 10.8, 18, 0.56 nM for MMP-1 ，MMP-2， MMP-3 ，MMP-8，MMP-9， MMP-13 ，respectively.

保管条件

Desiccated,Store at -80°C

入荷

Dry ice packs + Cold packs

この製品は冷冷この冷このこの製品の運送が必要です。地上およびその他の経済サービスは利用できません。

名前と識別子

異性体SMILES

COCCOC(=O)N1CCN(C(C1)C(=O)NO)S(=O)(=O)C2=CC(=C(C(=C2)F)OC3=CC=C(C=C3)Cl)F

PubChem CID

74439626

分子量

548.92